My interpretation is that the BLA will get a priority review if PolyHeme shows superiority vs the control arm and a standard review if it shows only non-inferiority.
Apart from the question of priority review, for a product that is this far along in development a Fast Track designation does not mean much.
Market Data 
Markets 
AI
